机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing 100050, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou 215123, China神经外科普外科苏州大学附属第二医院[3]Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China研究所北京市神经外科研究所首都医科大学附属天坛医院[4]Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China[5]Chinese Glioma Cooperative Group (CGCG), Beijing, China[6]China National Clinical Research Center for Neurological Diseases, Beijing, China
We investigated immune-related long non-coding RNAs (lncRNAs) that may be exploited as potential therapeutic targets in anaplastic gliomas. We obtained 572 lncRNAs and 317 immune genes from the Chinese Glioma Genome Atlas microarray and constructed immune-related lncRNAs co-expression networks to identify immune-related lncRNAs. Two additional datasets (GSE16011, REMBRANDT) were used for validation. Gene set enrichment analysis and principal component analysis were used for functional annotation. Immune-lncRNAs co-expression networks were constructed. Nine immune-related lncRNAs (SNHG8, PGM5-AS1, ST20-AS1, LINC00937, AGAP2-AS1, MIR155HG, TUG1, MAPKAPK5-AS1, and HCG18) signature was identified in patients with anaplastic gliomas. Patients in the low-risk group showed longer overall survival (OS) and progression-free survival than those in the high-risk group (P < 0.0001; P < 0.0001). Additionally, patients in the high-risk group displayed no-deletion of chromosomal arms 1p and/or 19q, isocitrate dehydrogenase wild-type, classical and mesenchymal TCGA subtype, G3 CGGA subtype, and lower Karnofsky performance score (KPS). Moreover, the signature was an independent factor and was significantly associated with the OS (P = 0.000, hazard ratio (HR) = 1.434). These findings were further validated in two additional datasets (GSE16011, REMBRANDT). Low-risk and high-risk groups displayed different immune status based on principal components analysis. Our results showed that the nine immune-related lncRNAs signature has prognostic value for anaplastic gliomas.
基金：
This work was supported by grants from Ministry of Science
and Technology of China Grant (2012CB825505 and 2011BAI08B08);
National Key Technology Research and Development Program of
the Ministry of Science and Technology of China (2013BAI09B03,
2014BAI04B02); National High Technology Research and Development
Program (No. 2012AA02A508); National Natural Science Foundation
of China (No. 91229121); Beijing Municipal Administration
of Hospitals’ Mission Plan (SML20150501); “13th Five-Year Plan”
National Science and Technology supporting plan (2015BAI09B04).
第一作者机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing 100050, China[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou 215123, China[5]Chinese Glioma Cooperative Group (CGCG), Beijing, China[6]China National Clinical Research Center for Neurological Diseases, Beijing, China
通讯作者：
通讯机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing 100050, China[2]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou 215123, China[5]Chinese Glioma Cooperative Group (CGCG), Beijing, China[6]China National Clinical Research Center for Neurological Diseases, Beijing, China
推荐引用方式(GB/T 7714)：
Wen Wang,Zheng Zhao,Fan Yang,et al.An immune-related lncRNA signature for patients with anaplastic gliomas[J].JOURNAL OF NEURO-ONCOLOGY.2018,136(2):263-271.doi:10.1007/s11060-017-2667-6.
APA：
Wen Wang,Zheng Zhao,Fan Yang,Haoyuan Wang,Fan Wu...&Jizong Zhao.(2018).An immune-related lncRNA signature for patients with anaplastic gliomas.JOURNAL OF NEURO-ONCOLOGY,136,(2)
MLA：
Wen Wang,et al."An immune-related lncRNA signature for patients with anaplastic gliomas".JOURNAL OF NEURO-ONCOLOGY 136..2(2018):263-271
